Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. LAL PATHLABS Gains 3%; BSE HEALTHCARE Index Up 1.2%
Thu, 4 Jul 14:15

DR. LAL PATHLABS Gains 3%; BSE HEALTHCARE Index Up 1.2%Image source: StarLineArts/www.istockphoto.com

DR. LAL PATHLABS share price has zoomed 3% and is presently trading at Rs 2,913.0.

Meanwhile, the BSE HEALTHCARE index is at 37,890.8 (up 1.2%).

Among the top gainers in the BSE HEALTHCARE index today are ASTRAZENECA PHARMA (up 12.7%) and Lupin (up 7.1%).

ERIS LIFESCIENCES (down 1.0%) and SUVEN PHARMACEUTICALS (down 1.0%) are among the top losers today.

Over the last one year, DR. LAL PATHLABS has moved up from Rs 2,252.6 to Rs 2,913.0, registering a gain of Rs 660.4 (up 29.3%).

On the other hand, the BSE HEALTHCARE index has moved up from 25,627.6 to 37,890.8, registering a gain of 47.9% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 96.8%), Cadila Healthcare (up 96.6%) and Lupin (up 95.7%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 80,166.1 (up 0.2%).

The top gainers among the BSE Sensex today are HCl Tech. (up 3.5%) and ICICI Bank (up 2.2%). The most traded stocks in the BSE Sensex are HDFC Bank and Tata Steel.

In the meantime, NSE Nifty is at 24,340.1 (up 0.2%). HCl Tech. and ICICI Bank are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,205.1 to 80,166.1, registering a gain of 14,961.1 points (up 22.9%).

DR. LAL PATHLABS Financial Update...

DR. LAL PATHLABS net profit grew 50.8% YoY to Rs 858 million for the quarter ended March 2024, compared to a profit of Rs 569 million a year ago. Net sales rose 11.1% to Rs 5,454 million during the period as against Rs 4,910 million in January-March 2023.

For the year ended March 2024, DR. LAL PATHLABS reported 50.3% increase in net profit to Rs 3,623 million compared to net profit of Rs 2,411 million during FY23. Revenue of the company grew 10.4% to Rs 22,266 million during FY24.

The current Price to earnings ratio of DR. LAL PATHLABS, based on rolling 12 month earnings, stands at 67.1.


Equitymaster requests your view! Post a comment on "DR. LAL PATHLABS Gains 3%; BSE HEALTHCARE Index Up 1.2%". Click here!